Teamwork Financial Advisors LLC Acquires 4,653 Shares of Pfizer Inc. (NYSE:PFE)

Teamwork Financial Advisors LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 10.3% in the 1st quarter, HoldingsChannel reports. The firm owned 50,040 shares of the biopharmaceutical company’s stock after buying an additional 4,653 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Pfizer were worth $1,268,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of PFE. Greenfield Savings Bank boosted its stake in shares of Pfizer by 4.0% during the first quarter. Greenfield Savings Bank now owns 37,333 shares of the biopharmaceutical company’s stock valued at $946,000 after purchasing an additional 1,451 shares in the last quarter. Apella Capital LLC lifted its holdings in Pfizer by 6.5% during the first quarter. Apella Capital LLC now owns 22,602 shares of the biopharmaceutical company’s stock worth $573,000 after buying an additional 1,374 shares during the period. Silverberg Bernstein Capital Management LLC boosted its position in Pfizer by 19.5% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 9,800 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 1,600 shares in the last quarter. JBGlobal.com LLC increased its holdings in shares of Pfizer by 20.6% in the 1st quarter. JBGlobal.com LLC now owns 16,455 shares of the biopharmaceutical company’s stock valued at $417,000 after acquiring an additional 2,816 shares during the period. Finally, Smith Anglin Financial LLC increased its holdings in shares of Pfizer by 31.0% in the 1st quarter. Smith Anglin Financial LLC now owns 10,211 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 2,418 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.37 on Wednesday. The company has a 50 day moving average price of $23.05 and a 200 day moving average price of $25.03. The firm has a market capitalization of $132.85 billion, a P/E ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.